Company Overview - Guoxin Health is a state-owned enterprise controlled by China Guoxin Holdings, aiming to build a leading health security service system in China [3] - The company covers over 190 medical insurance coordination areas, focusing on comprehensive management services for medical insurance funds, medical quality safety services, and drug/device supervision services [3][4] Financial Performance - As of the end of 2020, the total assets reached CNY 563.4 billion, with a net profit exceeding CNY 16 billion [4] - The company has set ambitious revenue growth targets, with compound annual growth rates (CAGR) for operating income from 2022 to 2024 projected at no less than 45%, 41.3%, and 37.8%, respectively [4] Business Strategy - The company operates under a "1+2" framework, supporting the national strategy of "Healthy China" through information technology and big data applications [3] - The business model includes a focus on digital medical insurance services, which encompass fund supervision, fund payment, and provincial medical insurance information services [5] Market Position and Competitive Advantage - Guoxin Health is the first company in China to support the implementation of payment reform for medical insurance, leveraging extensive experience and professional talent [5] - The company has initiated over 50 DRG (Diagnosis-Related Group) pilot projects and more than 20 DIP (Disease-Related Payment) projects across various cities [4][5] Employee and Organizational Structure - As of 2020, the company employed 1,244 staff members, focusing on cost reduction and efficiency improvement [6] - The organizational structure was upgraded in the first half of the year, dividing into four business units and seven regions to enhance customer engagement [6] Investor Relations - The company maintains strict adherence to information disclosure regulations, ensuring transparency and accuracy in communications with investors [6]

证券代码：000503 证券简称：国新健康 国新健康保障服务集团股份有限公司 投资者关系活动记录表 编号：2021－03 | --- | --- | --- | --- | --- | --- | |----------------|---------------------------------------------------------------|---------------|-------------|-------|-------| | | | | | | | | | | | | | | | 投资者关系 | √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | | | | 活动类别 | □新闻发布会 | □路演活动 | | | | | | □现场参观 | □其他 （ ） | | | | | | | | | | | | | 中金公司 于钟海、王之昊、韩蕊、王茜 UBS 资产管理 Cuicui | | | | | | | Segantii Fund Louiy | | | | | | | FranklinTempleton 吴晓薇 | | | | | | | 汇丰资管 Christ ...

证券代码：000503 证券简称：国新健康 1 国新健康保障服务集团股份有限公司 投资者关系活动记录表 编号：2021－04 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | □特定对象调研 □分析师会议 | | | | | | | | | | 投 ...

Group 1: Company Overview - Guoxin Health is a publicly listed company with the stock code 000503 [1] - The company focuses on providing health insurance and related services [2] Group 2: Investor Relations Activities - The investor relations activity recorded on December 6, 2021, included a teleconference with various investment firms [3] - Key participants included representatives from Huatai Securities, Harvest Fund, and other investment institutions [2] Group 3: DRG/DIP Business Overview - The company has over 50 DRG (Diagnosis-Related Group) pilot projects and 20 DIP (Diagnosis-Intervention Payment) projects [3] - The main project forms include service methods, information technology construction, and a combination of both [3] - The most common charging method involves information technology construction plus service, varying by region [3] Group 4: Financial Aspects - The company aims for profitability or at least break-even in its DRG/DIP business, with local government funding generally covering project costs [4] - Initial setup costs for the DRG project in Jinhua were around 3-4 million, with annual operational costs stabilizing at approximately 2 million [4] - The annual service fee for the DRG project in Liuzhou is around 1 million [4] Group 5: Future Business Strategy - The company emphasizes the importance of providing professional systems and technical services as a key focus for future business development [4] - There is a recognition that competition in the hospital sector will drive improvements in products and services [5] - The company plans to leverage its established standards and local adaptations to maintain a competitive edge in the market [5]

Group 1: Company Overview - Guoxin Health is a state-owned enterprise under China Guoxin Holdings, focusing on building a leading health assurance service system in China [2] - The company aims to provide fair and just health assurance services, with a business framework centered on comprehensive management of medical insurance funds, medical quality and safety services, and drug and device supervision [3] Group 2: Financial Performance - As of the end of 2020, the total assets reached CNY 563.4 billion [3] - The company has set performance unlocking conditions for its equity incentive plan, targeting a compound annual growth rate (CAGR) of at least 45%, 41.3%, and 37.8% for operating revenue from 2022 to 2024, with corresponding revenues expected to reach CNY 396.06 million, CNY 517.87 million, and CNY 645.50 million respectively [3] Group 3: Business Strategy and Growth - The company has established a strategic framework of "one body and two wings," focusing on digital health insurance as the core, with digital medical and digital pharmaceutical services as the wings [5] - The digital health insurance business has consistently accounted for over 50% of total revenue from 2019 to mid-2021, although it has faced negative gross margins due to high fixed labor costs [5] Group 4: Market Position and Future Outlook - The company has been proactive in the DRG/DIP payment reform, with over 50 pilot projects for DRG and around 20 for DIP already initiated [5] - By the end of 2025, it is expected that the DRG/DIP payment method will cover over 70% of medical insurance funds, with the company positioned to lead in this transformation [4] Group 5: Investor Engagement - The management has committed to transparent communication with investors, adhering to regulations for accurate and timely information disclosure [6] - The company has received positive responses from local governments regarding the implementation of the three-year action plan for DRG/DIP payment reform, with many provinces already initiating related work [6]

Group 1: Company Overview - Guoxin Health is a state-owned enterprise listed under China Guoxin Holdings, focusing on building a leading health assurance service system in China [2] - As of the end of 2020, the total assets reached CNY 563.4 billion, with a net profit exceeding CNY 16 billion [3] - The company aims to provide fair and just health assurance services, aligning with the national strategy of "Healthy China" [3] Group 2: Business Focus and Services - The company operates in three main business areas: comprehensive management of medical insurance funds, medical quality and safety services, and drug and medical device regulation services [3] - It covers over 190 medical insurance coordination areas, supporting the "Three Medical Linkage" reform [3] Group 3: Financial Performance and Growth Targets - The company has set ambitious performance targets for its equity incentive plan, aiming for a compound annual growth rate (CAGR) of at least 45%, 41.3%, and 37.8% in revenue from 2022 to 2024 compared to 2019 [4] - Expected revenues for 2022, 2023, and 2024 are CNY 396.06 million, CNY 517.87 million, and CNY 645.50 million respectively [4] Group 4: Market and Business Model Insights - The company is actively involved in the DRG/DIP payment reform, with over 50 DRG pilot projects and more than 20 DIP projects [5] - The DRG/DIP business model involves complex multi-disciplinary services, requiring significant talent and ongoing operational work [5] Group 5: Challenges and Strategic Directions - The company faces challenges with low gross margins, particularly in its digital medical insurance business, which has been operating at a loss [6] - Future strategies include enhancing operational efficiency, expanding hospital management services, and leveraging state-owned enterprise resources for business development [6] Group 6: Collaboration and Partnerships - In April 2021, Guoxin Health signed a cooperation agreement with Hangzhou Health Commission to develop commercial health insurance, aiming to streamline claims processes for residents [7] - The company has invested CNY 82 million in Beijing Yiyong Technology, focusing on building a tumor big data ecosystem [5] Group 7: Regulatory and Compliance - The management strictly adheres to information disclosure regulations, ensuring the accuracy and completeness of disclosed information [8]

Financial Performance - The company's revenue for Q3 2022 was ¥52,143,726.47, representing a 6.07% increase year-over-year, while total revenue for the year-to-date reached ¥134,546,259.88, up 32.18% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was -¥44,553,621.74, a decrease of 40.25% year-over-year, with a year-to-date net profit of -¥116,514,666.36, reflecting an 8.49% increase compared to the previous year[5]. - The company reported a basic earnings per share of -¥0.0491 for Q3 2022, down 39.12% year-over-year, and a diluted earnings per share of -¥0.0491, also down 39.12%[5]. - Total operating revenue for Q3 2022 reached ¥134,546,259.88, an increase of 32.2% compared to ¥101,789,615.66 in the same period last year[31]. - The net loss for Q3 2022 was ¥116,709,439.54, slightly improved from a loss of ¥127,102,873.73 in Q3 2021[31]. - The total profit (loss) for the period was -115,362,959.78, compared to -127,578,122.71 in the previous period, showing an improvement[33]. - The net profit (loss) attributable to shareholders of the parent company was -116,514,666.36, compared to -127,324,268.01 in the previous period[33]. - The total comprehensive income attributable to the parent company was -110,432,919.40, compared to -129,962,216.67 in the previous period[33]. - The basic and diluted earnings per share were both -0.1284, an improvement from -0.1417 in the previous period[33]. Expenses and Costs - Research and development expenses increased by 78.69% year-over-year to ¥37,280,844.39, indicating a significant investment in new products and technologies[10]. - Total operating costs for Q3 2022 were ¥268,392,665.84, up 15.3% from ¥232,718,054.41 in Q3 2021[31]. - Research and development expenses for Q3 2022 were ¥7,998,222.46, down 36.5% from ¥12,621,987.78 in the previous year[31]. - The company reported a credit impairment loss of ¥17,577,957.16, compared to a gain of ¥1,582,030.19 in the same period last year[31]. - The company reported a 600.40% increase in financial expenses to ¥131,924.79, primarily due to exchange rate fluctuations and reduced interest income[10]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,009,035,413.20, a decrease of 15.37% from the end of the previous year[5]. - The company's cash flow from operating activities showed a net outflow of -¥190,712,362.62 year-to-date, a decline of 28.79% compared to the same period last year[5]. - Cash and cash equivalents decreased to ¥151,724,911.90 from ¥352,886,146.28 at the beginning of the year, a decline of 57.0%[24]. - Total current assets as of September 30, 2022, were ¥683,988,218.47, down 22.0% from ¥877,200,636.09 at the start of the year[24]. - Total liabilities decreased to ¥327,241,510.48 from ¥405,082,955.22, a reduction of 19.2%[27]. - The company's equity attributable to shareholders decreased to ¥680,165,861.84 from ¥785,613,339.24, a decline of 13.4%[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 60,771[15]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 25.98% of shares, totaling 235,702,593 shares[15]. - The company has not disclosed any related party relationships among the top ten shareholders[15]. - The top ten shareholders do not include any parties that are considered acting in concert under the relevant regulations[15]. - The company has not reported any preferred shareholders or their holdings[18]. Investments and Future Plans - The company has invested 12 million RMB in Zhongzi Medical Emergency Guarantee Platform Co., Ltd., increasing its ownership to 8%[18]. - The company has paid the first installment of 6 million RMB for the investment in Zhongzi Medical[18]. - The company plans to raise up to 794.48 million RMB through a non-public offering of A-shares for various projects[21]. - The company plans to focus on market expansion and new product development in the upcoming quarters[29]. Organizational Changes - The organizational structure of the company has been adjusted to enhance operational efficiency[19]. - The company has changed its registered address to Qingdao, Shandong Province[20].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥82,402,533.41, representing a 56.57% increase compared to ¥52,629,413.09 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was -¥71,961,044.62, an improvement of 24.69% from -¥95,557,067.54 year-on-year[26]. - The net cash flow from operating activities was -¥83,916,625.54, which is 18.42% better than -¥102,863,770.73 in the previous year[26]. - The total assets at the end of the reporting period were ¥1,057,390,259.68, down 11.32% from ¥1,192,309,580.42 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company decreased by 8.24% to ¥720,861,090.30 from ¥785,613,339.24[26]. - The basic earnings per share improved to -¥0.0793, a 25.40% increase from -¥0.1063 in the same period last year[26]. - The weighted average return on net assets was -9.55%, an improvement of 0.93% from -10.48% in the previous year[26]. - The company reported a total of non-recurring gains and losses amounting to approximately 11.96 million, primarily from the recovery of previously impaired receivables and litigation compensation[32]. - The company's management expenses increased to ¥54,477,866.86, up 14.78% from ¥47,463,494.48[87]. - Investment income reported a loss of ¥472,966.17, a decline of 108.39% compared to a gain of ¥5,634,724.30 in the previous year[93]. - The company's cash and cash equivalents decreased by 42.56% to ¥202,684,001.68 from ¥352,886,146.28, primarily due to cash outflows from operating activities[87]. Business Strategy and Development - The company focuses on the "Health China" national strategy, aiming to become a leader in digital health insurance and services, with a strategic plan involving digital health insurance, digital healthcare, and digital pharmaceuticals[35]. - The company has successfully implemented DRG payment services, contributing to the reform of payment methods from quantity-based to quality-based, enhancing the performance of health insurance fund usage[36]. - The company has developed a comprehensive payment service using big data to objectively assess disease characteristics, improving transparency and efficiency in healthcare service management[37]. - The company has introduced an innovative outpatient payment model combining per capita payment and APG point system, achieving significant results in managing outpatient services[38]. - The company has established a big data fraud detection model to identify and predict fraudulent behaviors in health insurance, enhancing the monitoring capabilities of health insurance funds[42]. - The company has developed a credit evaluation system for health insurance, promoting a differentiated regulatory mechanism based on credit information and evaluation[43]. - The company provides a comprehensive audit management system for health insurance operations, ensuring effective oversight and management of healthcare expenditures[44]. - The company offers regional medical service quality supervision, aiming to improve healthcare service quality through real-time monitoring and evaluation[47]. - The company has created a hospital big data operation management service to optimize hospital performance under complex payment reform policies, enhancing both economic and social benefits[48]. - The company is actively promoting the integration of digital health management services, including chronic disease management and prescription circulation services[60][61]. - The company is leveraging artificial intelligence and big data to enhance its commercial health insurance third-party services, improving claims processing and risk control capabilities[62]. - The company is focused on enhancing its product and service offerings in the medical insurance sector, aiming for systematic product service and professional marketing[64]. - The company is committed to supporting the national healthcare reform policies, creating favorable development opportunities for its business[63]. Revenue and Growth - In the first half of 2022, the digital medical insurance business achieved revenue of ¥45,945,023.76, representing a year-on-year growth of 31.88%[68]. - The digital healthcare business achieved revenue of ¥8,385,673.18 in the first half of 2022, representing a year-on-year growth of 10.74%[70]. - The digital pharmaceutical business reported revenue of ¥27,987,074.59 in the first half of 2022, showing a significant year-on-year increase of 176.40%[72]. - The digital medicine segment saw a remarkable growth of 176.40%, with revenue rising to ¥27,987,074.59 from ¥10,125,678.48[90]. - The gross margin for the digital medicine segment improved by 88.27%, reflecting better cost control measures[90]. Risks and Challenges - The company faced risks and has outlined countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[5]. - The company is addressing financial risks by implementing comprehensive budget management and optimizing human resource management[113]. - The company faces competitive risks due to increasing market competition and plans to enhance its core competencies and optimize product upgrades[113]. - The company has faced significant uncertainty in its operations due to the unpredictable nature of the COVID-19 pandemic and its impact on the healthcare and pharmaceutical sectors[114]. - The company’s management has emphasized the importance of maintaining operational stability amid ongoing pandemic risks[114]. Corporate Governance and Structure - The company held its first extraordinary general meeting of 2022 on March 29, with a participation rate of 26.34%[117]. - The company has undergone changes in its board of directors, with several new appointments made on March 29, 2022[118]. - The company’s board of directors and supervisory board have been restructured, with new members elected during the recent meetings[121]. - The company has completed the election of the new board of directors and supervisory board, ensuring effective decision-making[164]. - The company has implemented a long-term incentive plan involving restricted stock, which received approval from the State-owned Assets Supervision and Administration Commission[123]. - The company did not report any objections during the public announcement period for its incentive plan, indicating strong internal support[123]. Shareholder Information - The total number of shares is 907,215,204, with 99.07% being unrestricted shares[171]. - The largest shareholder, China Ocean Holdings Development Co., Ltd., holds 25.98% of the shares, totaling 235,702,593[175]. - The company reported a total of 61,158 ordinary shareholders at the end of the reporting period[175]. - There were no significant changes in the number of shares held by major shareholders during the reporting period[175]. - The company has not reported any share buyback progress or changes in shareholding structure[171]. Miscellaneous - The company purchased agricultural products from Lichuan, Hubei, totaling 119,500 yuan as part of its social responsibility initiatives[131]. - The company has a related party debt balance of 164.24 million yuan at the end of the period, with no new additions or repayments during the reporting period[146]. - The company has no significant related party transactions during the reporting period[149]. - The company has no significant asset or equity disposals during the reporting period[108]. - The company has no loans, deposits, or other financial transactions with related financial companies[147][148].

Financial Performance - The company's operating revenue for 2021 was CNY 252,515,004.56, representing a 21.77% increase compared to CNY 207,372,157.90 in 2020[27] - The net profit attributable to shareholders was a loss of CNY 175,821,833.40, an improvement of 27.53% from a loss of CNY 242,605,400.28 in the previous year[27] - The net cash flow from operating activities was a negative CNY 104,821,324.48, which is a decline of 12.70% compared to negative CNY 93,006,322.85 in 2020[27] - The total assets at the end of 2021 were CNY 1,192,309,580.42, down 8.06% from CNY 1,296,817,917.19 at the end of 2020[27] - The basic earnings per share for 2021 was -CNY 0.1952, an improvement of 27.68% from -CNY 0.2699 in 2020[27] - The weighted average return on net assets was -20.13%, an improvement of 2.08% from -22.21% in the previous year[27] - The net profit after deducting non-recurring gains and losses was a loss of CNY 189,315,421.70, which is 21.60% better than the loss of CNY 241,487,204.53 in 2020[27] - The company's net assets attributable to shareholders decreased by 8.06% to CNY 785,613,339.24 at the end of 2021 from CNY 961,147,152.18 at the end of 2020[27] Cash Flow and Investment - The net cash flow from operating activities was -¥104,821,324.48 in 2021, a decrease of 12.70% compared to -¥93,006,322.85 in 2020[116] - The net cash flow from investment activities dropped significantly by 240.96% to -¥51,649,592.59 in 2021, primarily due to an investment of ¥82 million in Yiyong Technology[119] - The total cash inflow from financing activities increased by 54.94% to ¥77,468,580.00 in 2021, while cash outflow decreased by 67.55% to ¥62,532,773.89[116] - The company's cash and cash equivalents decreased by 8.19% to ¥352,886,146.28 at the end of 2021, down from ¥496,677,366.20 at the beginning of the year[122] - The total investment during the reporting period was 91,649,278.55 CNY, representing a significant decrease of 77.22% compared to the previous year's investment of 402,396,444.91 CNY[131] Revenue Segments - The digital medical business achieved revenue of ¥137,378,486.12, representing a year-on-year growth of 21.73%[76] - The digital healthcare business generated revenue of ¥52,197,614.55, with a year-on-year increase of 32.36%[78] - The digital pharmaceutical business reported revenue of ¥62,751,761.07, reflecting a year-on-year growth of 14.22%[80] - The revenue from digital healthcare services amounted to ¥137,378,486.12, accounting for 54.40% of total revenue, with a growth rate of 21.73% from the previous year[94] - The digital medicine segment generated revenue of ¥62,751,761.07, which is 24.85% of total revenue, with a year-on-year growth of 14.22%[94] - The digital medical services segment reported revenue of ¥52,197,614.55, representing 20.67% of total revenue, with a significant growth rate of 32.36%[94] Operational Strategies and Innovations - The company aims to become a leader in digital health insurance services, focusing on integrated management of health insurance funds, medical quality safety services, and drug/device regulatory services[43] - The company is actively involved in the implementation of DRG payment reform, enhancing the performance of health insurance fund usage[44] - The company has developed a comprehensive knowledge system for health insurance, medical, and pharmaceutical sectors, utilizing AI and big data to improve service transparency and operational management[45] - The company has successfully transitioned from quantity-based to quality-based payment methods in health insurance, reflecting its commitment to improving healthcare outcomes[44] - The company has implemented a flying inspection system to combat fraud in medical insurance, focusing on compliance in medical institutions and pharmacies[53] - The company is enhancing its information technology services to meet diverse regional needs, improving the governance capabilities of medical insurance systems[54] - The company is advancing the construction of a digital drug supervision platform covering the entire lifecycle of pharmaceuticals, promoting digital transformation in drug regulation[152] Challenges and Risks - The company faces risks in its operational management, which are discussed in detail in the report[7] - The company has faced challenges due to the COVID-19 pandemic but has managed to maintain steady growth in its core business[42] - The company faces competitive risks due to increasing market competition and plans to optimize product upgrades and innovate market expansion strategies[157] - The company is implementing comprehensive budget management to mitigate financial risks associated with rising human resource costs[157] - The company is closely monitoring policy changes in the healthcare sector to adapt its business structure and governance levels accordingly[157] Governance and Compliance - The company maintains complete independence in operations, assets, personnel, and finance from its controlling shareholders, ensuring no competitive relationship exists[172] - The company has established an independent financial department with a standardized accounting system, allowing for autonomous financial decision-making[173] - The company has a clear delineation of asset ownership, with all operational assets fully controlled by the company[172] - The company has established a robust governance framework, including a board of directors and supervisory board, to ensure independent oversight[175] - The company has no instances of asset or funds being occupied by shareholders, safeguarding its interests[172] - The company is committed to maintaining compliance with all regulatory requirements, ensuring transparency in operations[171] Future Outlook - The company has outlined a future outlook with a projected revenue growth of 20% for the next fiscal year[164] - New product development initiatives include the launch of a telehealth service expected to generate an additional 100 million in revenue[165] - The company is expanding its market presence by entering three new provinces, aiming for a 10% market share in these regions within two years[166] - The company aims to enhance its competitive edge in the healthcare fund service sector through the development of a data middle platform, which is expected to improve response speed to new demands and reduce project costs[115] Human Resources and Management - The company has implemented a new incentive program for employees, which is expected to improve productivity by 15%[168] - The company has a total of 266,000 shares granted to executives as part of the equity incentive plan, reflecting a commitment to align management interests with shareholder value[180] - The company has a total of 8 independent directors and supervisors, with various roles in other organizations, ensuring diverse governance[199] - The company’s management team includes professionals with extensive backgrounds in finance, law, and healthcare, enhancing its operational capabilities[198]

Financial Performance - The company's operating revenue for Q1 2022 was ¥37,951,381.37, representing a 38.43% increase compared to ¥27,415,350.34 in the same period last year[4] - The net profit attributable to shareholders was -¥49,423,957.16, an improvement of 12.15% from -¥56,262,309.65 year-on-year[4] - The company reported a net loss of ¥48,421,498.88 for the current period, compared to a profit of ¥1,002,458.28 in the previous period[24] - Total comprehensive income for the period was -49,442,066.65, compared to -53,418,803.17 in the same period last year, indicating a reduction in losses[31] - The net profit for the first quarter was -49,422,023.57, compared to -56,375,139.39 in the previous year, showing an improvement of approximately 12.4%[30] - The total operating profit was -49,428,527.65, an improvement from -56,366,627.23 year-over-year, reflecting a positive trend in operational performance[30] Cash Flow and Liquidity - The net cash flow from operating activities was -¥101,791,799.62, a decline of 20.98% compared to -¥84,141,757.17 in the previous year[4] - Cash inflow from operating activities totaled 23,618,915.13, up from 12,570,829.37 in the previous year, reflecting a significant increase of approximately 88%[32] - Cash outflow for operating activities was 125,410,714.75, compared to 96,712,586.54 in the previous year, representing an increase of about 30%[35] - The cash and cash equivalents at the end of the period were 238,032,127.40, down from 402,764,350.63 at the end of the previous year[38] - The cash and cash equivalents decreased by 30.93% to ¥243,721,065.22, primarily due to net cash outflows from operating activities[7] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,106,807,386.22, down 7.17% from ¥1,192,309,580.42 at the end of the previous year[4] - Total liabilities decreased to ¥369,022,827.67 from ¥405,082,955.22, showing a reduction of approximately 8.9%[21] - The total equity attributable to shareholders decreased to ¥736,169,339.00 from ¥785,613,339.24, a decline of about 6.3%[24] - The balance of contract assets rose by 112.33% to ¥49,317,794.15, driven by increased revenue during the reporting period[7] - Contract liabilities increased to ¥63,394,395.13 from ¥59,549,813.53, reflecting a growth of approximately 3.1%[21] Research and Development - The company increased its research and development expenses to ¥2,042,652.21, a significant rise of 195.89% from ¥690,346.50 in the same period last year, indicating a focus on new product and technology development[7] - The company reported a 62.09% increase in development expenditures, totaling ¥26,119,001.73, reflecting enhanced investment in new products and technologies[7] Shareholder Information - The total number of common shareholders at the end of the reporting period is 64,708[10] - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 25.98% of shares, totaling 235,702,593 shares[10] - The company has not disclosed any related party relationships among the top ten shareholders[10] - The company has not reported any changes in the status of shares held by major shareholders[10] Other Notable Information - The company held its first extraordinary general meeting of 2022 on March 29, 2022, to elect the new board of directors and supervisory board[14] - The company has not indicated any plans for market expansion or new product development in the current report[10] - The company recorded a total of ¥422,225.26 in non-recurring gains and losses, mainly from project investment income and government subsidies[6] - The company incurred a credit impairment loss of -2,763,987.71, compared to -12,143,044.44 in the previous year, indicating a significant reduction in credit losses[30] - The weighted average return on net assets was -6.50%, slightly down from -6.03% in the previous year[4]